INTRAOPERATIVE FLUORESCENCE STAINING OF MALIGNANT BRAIN TUMORS USING 5-AMINOFLUORESCEIN-LABELED ALBUMIN
- 1 March 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Operative Neurosurgery
- Vol. 64 (3), ons53-ons61
- https://doi.org/10.1227/01.neu.0000335787.17029.67
Abstract
The newly developed conjugate 5-aminofluorescein (AFL)-human serum albumin (HSA) was investigated in a clinical trial for fluorescence-guided surgery of malignant brain tumors to assess its efficacy and tolerability. AFL, covalently linked to human serum albumin at a molar ratio of 1:1, was administered intravenously 0.5 to 4 days before surgery at 0.5 or 1.0 mg/kg of body weight to 13 patients aged 38 to 71 years who were suspected of having malignant gliomas. Fluorescence guidance using a 488-nm argon laser was performed during surgery at will. The extent of tumor resection was verified by early postoperative magnetic resonance imaging. Fluorescent and nonfluorescent samples were collected for neuropathology. Blood samples for laboratory and pharmacokinetic analyses were taken over the course of 4 weeks. Fluorescence staining of tumor tissue was bright in 11 patients (84%), resulting in complete resection of fluorescent tumor tissue in 9 patients (69%). In 2 patients, residual fluorescent tumor tissue was also confirmed by magnetic resonance imaging. Neither bleaching nor penetration of AFL-HSA into the surrounding brain edema or into necrotic tissue was seen. The agreement between fluorescence and histopathology in tumor samples and samples of the tumor border was 83.3%. There were no toxic side effects. The quality of fluorescence was independent of the dose administered. The optimal time for surgery is between 1 and 4 days after AFL-HSA administration. Tumor fluorescence using AFL-HSA made fluorescence-guided brain tumor resection possible, demonstrating that albumin is a suitable carrier system for selective targeting of aminofluorescein into malignant gliomas.Keywords
This publication has 35 references indexed in Scilit:
- Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinomaInvestigational New Drugs, 2006
- Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trialThe Lancet Oncology, 2006
- Initial Experience with an Ultrasound-Integrated Single-Rack Neuronavigation SystemActa Neurochirurgica, 2001
- Pharmacokinetics of methotrexate???albumin conjugates in tumor-bearing ratsAnti-Cancer Drugs, 1997
- Use of intraoperative ultrasound for localizing tumors and determining the extent of resection: a comparative study with magnetic resonance imagingJournal of Neurosurgery, 1996
- Circumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicinEuropean Journal of Cancer, 1995
- Early Postoperative Magnetic Resonance Imaging after Resection of Malignant GliomaNeurosurgery, 1994
- Design of compounds having enhanced tumour uptake, using serum albumin as a carrier—part II. In vivo studiesInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1992
- Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part INuclear Medicine and Biology, 1989
- The Clinical Use of Fluorescein in NeurosurgeryJournal of Neurosurgery, 1948